Physical fitness · women receiving adjuvant therapy (chemo‐ or radiotherapy or both) for breast cancer
1 finding from 1 review
Fatigue · women receiving adjuvant therapy (chemo‐ or radiotherapy or both) for breast cancer
1 finding from 1 review
Cancer‐specific quality of life · women receiving adjuvant therapy (chemo‐ or radiotherapy or both) for breast cancer
1 finding from 1 review
Health‐related quality of life · women receiving adjuvant therapy (chemo‐ or radiotherapy or both) for breast cancer
1 finding from 1 review
Cancer site‐specific quality of life · women receiving adjuvant therapy (chemo‐ or radiotherapy or both) for breast cancer
1 finding from 1 review
Depression · women receiving adjuvant therapy (chemo‐ or radiotherapy or both) for breast cancer
1 finding from 1 review
Cognitive function · women receiving adjuvant therapy (chemo‐ or radiotherapy or both) for breast cancer
1 finding from 1 review
Adverse events: lymphoedema · women receiving adjuvant therapy (chemo‐ or radiotherapy or both) for breast cancer
1 finding from 1 review
Adverse effects · patients with dysphagia in oesophageal cancer
Brachytherapy showed no clear difference in adverse effects compared with brachytherapy plus radiotherapy (moderate certainty).
1 finding from 1 review
Adverse effects ‐ stricture · patients with dysphagia in oesophageal cancer
Brachytherapy showed no clear difference in adverse effects ‐ stricture compared with brachytherapy plus radiotherapy (high certainty).
1 finding from 1 review
Intervention not reported
PFS (stage III/IV) Median · women with advanced (stage III/IV) endometrial cancer after surgery and radiotherapy
The intervention showed no clear difference in PFS (stage III/IV) Median (moderate certainty).
1 finding from 1 review
Progression‐free survival · patients with epithelial ovarian cancer
Maintenance chemotherapy showed no clear difference in 3‐year PFS compared with maintenance radiotherapy (low certainty).
3 findings from 1 review
RR 1.07 [0.75, 1.54]
1 study · 141 participants
Low
RR 0.86 [0.55, 1.37]
1 study · 141 participants
Low
RR 0.89 [0.51, 1.55]
1 study · 141 participants
Low
3‐year OS · patients with epithelial ovarian cancer
Maintenance chemotherapy showed no clear difference in 3‐year OS compared with maintenance radiotherapy (low certainty).
1 finding from 1 review
5‐year OS · patients with epithelial ovarian cancer
Maintenance chemotherapy showed no clear difference in 5‐year OS compared with maintenance radiotherapy (low certainty).
1 finding from 1 review
10‐year OS · patients with epithelial ovarian cancer
Maintenance chemotherapy showed no clear difference in 10‐year OS compared with maintenance radiotherapy (low certainty).
1 finding from 1 review
Time to death from prostate cancerMedian · clinically localized and locally advanced prostate cancer
Dose‐escalated RT showed no clear difference in time to death from prostate cancer compared with conventional dose RT (moderate certainty).
1 finding from 1 review
Severe RT toxicity (grade ≥ 3) · clinically localized and locally advanced prostate cancer
Dose‐escalated RT probably leads to higher severe RT toxicity (grade ≥ 3) compared with conventional dose RT (moderate certainty).
1 finding from 1 review
Time to death from any cause · clinically localized and locally advanced prostate cancer
Dose‐escalated RT showed no clear difference in time to death from any cause compared with conventional dose RT (moderate certainty).
1 finding from 1 review
Time to distant metastasis · clinically localized and locally advanced prostate cancer
Dose‐escalated RT showed no clear difference in time to distant metastasis compared with conventional dose RT (moderate certainty).
1 finding from 1 review
Overall RT toxicity (grade ≥ 1) · clinically localized and locally advanced prostate cancer
Dose‐escalated RT may leads to higher overall RT toxicity (grade ≥ 1) compared with conventional dose RT (low certainty).
1 finding from 1 review